A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy

Who May Qualify: - Patients of any gender at least 6 years of age, diagnosed with DMD (according to genetic test) and have received a prescription for oral givinostat in accordance with the USPI. - Patient has provided willing to sign a consent form (and assent when applicable) for participation in the study. - Patient's index date (first date of givinostat treatment) is no more than 6 months prior to signing of willing to sign a consent form. - Patient has the required data available (DMD diagnosis, givinostat administration \[dose and schedule\], laboratory results \[hematology and triglycerides\]) for addressing the study objectives for the period between index date and study entry (for patients enrolled after the index date). Who Should NOT Join This Trial: - Patient previously received givinostat (commercial or investigational product) and permanently discontinued treatment or patient started commercial givinostat for \> 6 months before signing of willing to sign a consent form. Always talk to your doctor about whether this trial is right for you.